BPMX - BioPharmX Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
0.2324
+0.0053 (+2.33%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.2271
Open0.2300
Bid0.0000 x 4000
Ask0.0000 x 3000
Day's Range0.2235 - 0.2350
52 Week Range0.1000 - 0.5000
Volume1,940,172
Avg. Volume5,065,676
Market Cap44.509M
Beta-0.39
PE Ratio (TTM)N/A
EPS (TTM)-0.1370
Earnings DateJun 11, 2018 - Jun 15, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.05
Trade prices are not sourced from all markets
  • PR Newswire5 days ago

    New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatology

    MENLO PARK, Calif., June 19, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology – ranging from regulatory pathways to market access and from infectious diseases to antibiotic resistance – will inform the company's efforts by providing the kind of strategic expertise needed to position BioPharmX as a leader in patient-centric dermatology.

  • ACCESSWIRE5 days ago

    Blog Exposure - bluebird bio Announces Encouraging New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin(TM) Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia

    LONDON, UK / ACCESSWIRE / June 19, 2018 / If you want access to our free research report on bluebird bio, Inc. (NASDAQ: BLUE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BLUE as the Company's latest news hit the wire. On June 15, 2018, the Company announced that it will present new data from the completed Phase-1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase-3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, at the 23rd Annual Congress of the European Hematology Association in Stockholm on June 16, 2018. Active-Investors.com is currently working on the research report for BioPharmX Corporation (NYSE: BPMX), which also belongs to the Healthcare sector as the Company bluebird bio.

  • ACCESSWIRE5 days ago

    Free Technical Research on BioPharmX and Three More Biotech Equities bio

    LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on BPMX sign up now at www.wallstequities.com/registration. On Monday, June 18, 2018, the Dow Jones Industrial Average and the S&P 500 edged 0.41% and 0.21% lower, respectively at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), BioPharmX Corp. (NYSE AMER: BPMX), BioTime Inc. (NYSE AMER: BTX), and bluebird bio Inc. (NASDAQ: BLUE).

  • PR Newswire16 days ago

    BioPharmX Reports First Quarter 2019 Financial Results

    MENLO PARK, Calif. , June 7, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today reports financial ...

  • ACCESSWIRE17 days ago

    BioPharmX Displays Progress in BPX-01 and BPX-04 Clinicals, Pipeline Review and Target

    NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on BioPharmX Corporation (NYSE American: BPMX), a pharmaceutical company that provides technologies for prescription, over-the-counter, and supplement applications in the health and wellness markets, including dermatology and women's health. BioPharmX has successfully completed a phase 2b trial for BPX-01 and is preparing for phase 3 trials in acne. The past one year has been filled with numerous milestones for BioPharmX.

  • PR Newswirelast month

    BioPharmX Studies Show Hydrophilic Topical Minocycline Gels May Be the Preferred Treatment Option for Acne, Rosacea Patients

    MENLO PARK, Calif., May 24, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will present research showing that the topical delivery of minocycline in a gel formulation may offer a more targeted path to treating acne and rosacea than oral formulations that could make it the preferred treatment option for patients with those indications. The poster presentation, "Early Data from BPX-04 Topical Minocycline Gel for Rosacea Supported by Data From BPX-01 Topical Minocycline Gel for Acne: A Review," will be shared at the Congress of Clinical Dermatology, May 25-28, in Miramar Beach, Fla. The presentation concludes that, because topical minocycline formulations may avoid systemic side effects commonly associated with oral formulations of minocycline, as well as the cutaneous irritation common in other topical treatments, dermatologists may prefer these formulations for treatment of acne and rosacea.

  • BioPharmX Corporation (NYSEMKT:BPMX): What Does The Future Look Like?
    Simply Wall St.last month

    BioPharmX Corporation (NYSEMKT:BPMX): What Does The Future Look Like?

    The latest earnings release BioPharmX Corporation’s (AMEX:BPMX) announced in January 2018 showed company earnings became less negative compared to the previous year’s level – great news for investors Investors mayRead More...

  • GlobeNewswirelast month

    Factors of Influence in 2018, Key Indicators and Opportunity within Energy Transfer Equity, Mednax, BioPharmX, Owens & Minor, SunPower, and Convergys — New Research Emphasizes Economic Growth

    NEW YORK, May 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Energy ...

  • Why BioPharmX Corporation’s (NYSEMKT:BPMX) Investor Composition Impacts Your Returns
    Simply Wall St.2 months ago

    Why BioPharmX Corporation’s (NYSEMKT:BPMX) Investor Composition Impacts Your Returns

    In this article, I’m going to take a look at BioPharmX Corporation’s (AMEX:BPMX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...

  • PR Newswire2 months ago

    BioPharmX Reports Fourth Quarter and Full Year 2018 Financial Results

    MENLO PARK, Calif. , April 26, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today reports financial ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Trending Tickers: BioPharmX and MediWound

    NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Stock markets rallied Tuesday on gains from the energy and consumer discretionary sector. Wall Street appears to be eagerly awaiting details from the Federal ...

  • PR Newswire3 months ago

    BioPharmX Cancels Presentation at Oppenheimer's 28th Annual Healthcare Conference Due to Severe Weather

    MENLO PARK, Calif. , March 20, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announces that it has cancelled ...

  • PR Newswire3 months ago

    U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug Compositions

    MENLO PARK, Calif., March 20, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the U.S. Patent and Trademark Office has granted the first in what the company expects will be a new family of patents protecting its novel topical gel delivery system that allows for greater bioavailability of an active pharmaceutical ingredient (API) . The patent (U.S. Patent No. 9,918,998), entitled "Pharmaceutical Tetracycline Composition For Dermatological Use," covers a topical composition comprised of minocycline or another tetracycline-class drug and a method for making such compositions. This is the fourth U.S. patent issuance BioPharmX has received.

  • PR Newswire3 months ago

    BioPharmX to Present at Oppenheimer's 28th Annual Healthcare Conference

    MENLO PARK, Calif. , March 14, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announces that it will present ...

  • Loss-Making BioPharmX Corporation (NYSEMKT:BPMX) Expected To Breakeven
    Simply Wall St.4 months ago

    Loss-Making BioPharmX Corporation (NYSEMKT:BPMX) Expected To Breakeven

    BioPharmX Corporation’s (AMEX:BPMX): BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women’s health markets. The US$37.11M market-cap posted aRead More...

  • PR Newswire4 months ago

    BioPharmX to Present at 30th Annual ROTH Conference

    MENLO PARK, Calif. , March 5, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announces that it will present ...

  • PR Newswire5 months ago

    BioPharmX To Present Data On New Fluorescence Lifetime Imaging Microscopy to Measure How Effectively Topically Applied Minocycline Reaches Targets in Skin

    MENLO PARK, Calif., Jan. 26, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announced that a revolutionary technique to measure how effectively a single dose of topically applied minocycline reached the epidermis and pilosebaceous unit of human facial skin may potentially explain early onset of efficacy observed in two investigational BioPharmX drugs. The measurement was accomplished using fluorescence lifetime imaging microscopy (FLIM) to visualize the delivery of BPX-011 for acne and BPX-041 for rosacea. The specificity and sensitivity of the technique enabled researchers to begin quantifying the local distribution of minocycline in a given layer of skin.

  • PR Newswire5 months ago

    BioPharmX To Present BPX-04 Rosacea Data At Two Leading Clinical Conferences This Month

    MENLO PARK, Calif., Jan. 12, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will present to the medical community preliminary data from the treatment of rosacea using its novel topical gel, BPX-04. BPX-04 is the company's latest addition to its clinical pipeline.  It is the second product built on the proprietary, patent-pending BioPharmX hydrophilic topical delivery system.

  • ACCESSWIRE5 months ago

    Free Post Earnings Research Report: BioPharmX’s Adjusted EPS Beat Expectations

    LONDON, UK / ACCESSWIRE / January 09, 2018 / Active-Investors.com has just released a free earnings report on BioPharmX Corp. (NYSE: BPMX ). If you want access to this report all you need to do is sign ...

  • How Do Analysts See BioPharmX Corporation (NYSEMKT:BPMX) Performing In The Years Ahead?
    Simply Wall St.6 months ago

    How Do Analysts See BioPharmX Corporation (NYSEMKT:BPMX) Performing In The Years Ahead?

    The most recent earnings announcement BioPharmX Corporation’s (AMEX:BPMX) released in October 2017 showed that losses became smaller relative to the prrior year’s level – great news for investors Below isRead More...

  • How BioPharmX Corporation’s (NYSEMKT:BPMX) EPS Growth Stacks Up Against Industry Performance
    Simply Wall St.6 months ago

    How BioPharmX Corporation’s (NYSEMKT:BPMX) EPS Growth Stacks Up Against Industry Performance

    Examining how BioPharmX Corporation (AMEX:BPMX) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense check toRead More...

  • ACCESSWIRE6 months ago

    Blog Exposure - MabVax Therapeutics Completes Enrollment and Dosing In Initial Cohort of Phase-1 Trial of Its Cancer Drug MVT-1075

    Stock Monitor: BioPharmX Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors issued a free report on MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX ) ("MabVax"), ...

  • BioPharmX Corp. :BPMX-US: Earnings Analysis: Q3, 2018 By the Numbers : December 13, 2017
    Capital Cube6 months ago

    BioPharmX Corp. :BPMX-US: Earnings Analysis: Q3, 2018 By the Numbers : December 13, 2017

    Categories: Yahoo FinanceGet free summary analysis BioPharmX Corp. reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of BioPharmX Corp. – Supernus Pharmaceuticals, Inc., Foamix Pharmaceuticals Ltd., Achaogen, Inc. and Zogenix, Inc. (SUPN-US, FOMX-US, AKAO-US and ZGNX-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)